Previous 10 | Next 10 |
2023-09-27 13:48:39 ET Gainers: ShiftPixy ( PIXY ) +92% . SciSparc Ltd ( SPRC ) +42% . MSP Recovery ( LIFW ) +41% . Biohaven ( BHVN ) +28% . MillerKnoll ( MLKN ) +28% . American Strategic Investment Co ( NYC ) +22% . ...
2023-09-27 12:00:40 ET Shares of Biohaven (NYSE: BHVN) skyrocketed by 28.2% as of 11:10 a.m. ET Wednesday after the biopharmaceutical company submitted a regulatory filing to the Securities and Exchange Commission that included a new investor presentation. The big news in that n...
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) is one of today's top gainers. The company's shares are currently up 30.31% on the day to $23. Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsych...
2023-09-27 09:46:22 ET More on Biohaven Biohaven's Valuation Challenge: Weighing Potential Against Setbacks Biohaven falls as FDA rejects filing for movement disorder therapy Seeking Alpha’s Quant Rating on Biohaven Historical earnings data for Biohave...
Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy PR Newswire - Taldefgrobep alfa is the only myostatin inhibitor in clinical development that targets both myostatin and activin A signaling, two key regulators of muscle mass...
Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies PR Newswire Examination of EEG in healthy subjects administered single...
2023-09-02 12:00:00 ET Summary The decelerating COVID-19 portfolio and underperforming bolt-on acquisitions have directly contributed to PFE's lowered FY2023 guidance range. In an attempt to boost its pipeline, thanks to the patent cliff from 2025 onwards, the company has also emb...
2023-08-28 02:26:53 ET Summary Biohaven faces FDA rejection for troriluzole; explores further discussions and potential subgroup focus. Despite FDA setback, Biohaven maintains a strong cash position, diversified pipeline, and ongoing R&D efforts. Given current uncertaintie...
2023-07-31 12:09:38 ET Biohaven press release ( NYSE: BHVN ): Q2 Non-GAAP EPS of -$1.25 misses by $0.02 . Cash, cash equivalents, and marketable securities totaled $349.0 million as of June 30, 2023. For further details see: Biohaven Non-GAAP EPS of -$1....
Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy PR Newswire Taldefgrobep alfa, in Phase 3 global clinical development for Spinal Muscular Atrophy, granted EU Orphan Drug Designation in addition to previously receiving Fast Track and...
News, Short Squeeze, Breakout and More Instantly...
Biohaven Pharmaceutical Holding Company Ltd. Company Name:
BHVN Stock Symbol:
NYSE Market:
Biohaven Pharmaceutical Holding Company Ltd. Website:
2024-05-29 12:00:07 ET Brian Skorney from Robert W. Baird issued a price target of $58.00 for BHVN on 2024-05-29 09:57:00. The adjusted price target was set to $58.00. At the time of the announcement, BHVN was trading at $30.31. The overall price target consensus is at $...
2024-05-29 11:00:21 ET Leonid Timashev from RBC Capital issued a price target of $59.00 for BHVN on 2024-05-29 09:14:00. The adjusted price target was set to $59.00. At the time of the announcement, BHVN was trading at $28.69. The overall price target consensus is at $23...